Omar Elmadhoun

Dr. Omar Elmadhoun


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2026 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
SSShashank Shekhar
Shashank Shekhar
AAAnkit Agrawal
Ankit Agrawal
HAHussein Almadhoun
Hussein Almadhoun
PWPatrick M. Wieruszewski
Patrick M. Wieruszewski
GMGauranga Mahalwar
Gauranga Mahalwar
OEOmar Elmadhoun
Omar Elmadhoun

23 January 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
OEOmar Elmadhoun
Omar Elmadhoun
JHJeffrey Huang
Jeffrey Huang
AAArnoley Abcejo
Arnoley Abcejo
MMMichael P. Merren
Michael P. Merren
Mortality rates from pulmonary embolism (PE) remain significant, highlighting the need for alternative treatment strategies beyond traditional anticoagulation. Percutaneous interventions, including mechanical thrombectomy and catheter-directed thrombolysis, are emerging as promising options. Given the complex pathophysiology and unique risk profiles of these patients, meticulous multidisciplinary planning is essential. Anesthesiologists play a central role in coordinating care and managing perioperative risks to improve outcomes. This article provides insights into best safety practices and shares experiences from a leading quaternary center. It offers guidance for anesthesia providers to proactively engage in comprehensive risk stratification, participate in multidisciplinary discussions, and support robust contingency planning for managing PE patients undergoing percutaneous interventions in non-operating room anesthesia settings.

19 April 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
Krzysztof LaudanskiKrzysztof Laudanski
Krzysztof Laudanski
OEOmar Elmadhoun
Omar Elmadhoun
AMAmal Mathew
Amal Mathew
YKYul Kahn-Pascual
Yul Kahn-Pascual
MKMitchell Kerfeld
Mitchell Kerfeld
FRFrancisco Eduardo Gomez Romero
Francisco Eduardo Gomez Romero
Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant demyelinating neuropathy characterized by an increased susceptibility to peripheral nerve injury from trauma, compression, or shear forces. Patients with this condition are unique, necessitating distinct considerations for anesthesia and surgical teams. This review describes the etiology, prevalence, clinical presentation, and management of HNPP and presents contemporary evidence and recommendations for optimal care for HNPP patients in the perioperative period. While the incidence of HNPP is reported at 7–16:100,000, this figure may be an underestimation due to underdiagnosis, further complicating medicolegal issues. With the subtle nature of symptoms associated with HNPP, patients with this condition may remain unrecognized during the perioperative period, posing significant risks. Several aspects of caring for this population, including anesthetic choices, intraoperative positioning, and monitoring strategy, may deviate from standard practices. As such, a tailored approach to caring for this unique population, coupled with meticulous preoperative planning, is crucial and requires a multidisciplinary approach.

15 December 2025 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
RLRosa Labanca
Rosa Labanca
JUJacopo D’Andria Ursoleo
Jacopo D’Andria Ursoleo
SFStefano Fresilli
Stefano Fresilli
ABAlice Bottussi
Alice Bottussi
DPDomenico Pontillo
Domenico Pontillo
FMFabrizio Monaco
Fabrizio Monaco
Clevidipine is an ultrafast-acting dihydropyridine calcium channel antagonist with selective arteriolar-dilating effects that may be suitable for afterload

10 November 2024 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
TPTyler E. Powell
Tyler E. Powell
TLTheodore O. Loftsgard
Theodore O. Loftsgard
AAArnoley S. Abcejo
Arnoley S. Abcejo
OEOmar Elmadhoun
Omar Elmadhoun

27 August 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
MMMichael P. Merren
Michael P. Merren
MPMitchell Padkins
Mitchell Padkins
HCHector Cajigas
Hector Cajigas
NNNewton Neidert
Newton Neidert
AAArnoley Abcejo
Arnoley Abcejo
OEOmar Elmadhoun
Omar Elmadhoun
Pulmonary embolism (PE) embodies a large healthcare burden globally and is the third leading cause of morbidity and mortality worldwide. Submassive (intermediate-risk) PE accounts for 40% of this burden. However, the optimal treatment pathway for this population remains complex and ill-defined. Catheter-directed interventions (CDIs) have shown promise in directly impacting morbidity and mortality while demonstrating a favorable success rate, safety profile, and decreased length of stay (LOS) in the intensive care unit and hospital. This retrospective review included 22 patients (50% female) with submassive PE who underwent mechanical thrombectomy (MT). A total of 45% had a contraindication to thrombolytics, the mean pulmonary embolism severity index was 127, 36% had saddle PE, the average decrease in mean pulmonary artery pressure (PAP) was 7.2 mmHg following MT, the average LOS was 6.9 days, the 30-day mortality rate was 9%, the major adverse event (MAE) rate was 9%, and the readmission rate was 13.6%. A total of 82% had successful removal of thrombus during MT with no major bleeding complications, intracranial hemorrhage events, or device-related deaths. Acknowledging the limitation of our small sample size, our data indicate that MT in the intermediate-high-risk submassive pulmonary embolism (PE) cohort resulted in a decreased hospital length of stay (LOS) and in-hospital mortality compared to standard anticoagulation therapy alone.